Cathay International Holdings Ld Result of AGM (7289B)

TIDMCTI

RNS Number : 7289B

Cathay International Holdings Ld

10 June 2019

Cathay International Holdings Limited

("Cathay" or the "Company")

Results of Annual General Meeting ("AGM")

Hong Kong, 10 June 2019 - Cathay International Holdings Limited (LSE: CTI.L), an operator and investor in the growing healthcare sector in the People's Republic of China, today announces that at the AGM held earlier today, all resolutions as set out in the Notice of AGM dated 17 April 2019 were duly passed. The final poll voting results for each resolution are shown in the table below:

 
 Ordinary resolutions                     For   Against   Total votes   Withheld 
 1. Report and Accounts           441,697,339   141,975   441,839,314      1,920 
                                 ------------  --------  ------------  --------- 
 2. Re-election of Mr. 
  Lee Jin-Yi as Executive 
  Director                        441,695,587   138,639   441,834,226      7,008 
 3. Re-election of Mr. 
  Siu Ka Chi Eric as Executive 
  Director                        441,695,587   138,639   441,834,226      7,008 
 4. Re-election of Mr. 
  Patrick Sung as Executive 
  Director                        441,695,587   138,639   441,834,226      7,008 
 5. Re-election of Dr. 
  Chan Ching Har Eliza as 
  Independent Non-Executive 
  Director                        441,695,587   138,639   441,834,226      7,008 
 6. Reappointment of BDO 
  as Auditor                      441,823,380    15,954   441,839,334      1,900 
 7. Authority to allot 
  new shares                      441,696,508   139,618   441,836,126      5,108 
                                 ------------  --------  ------------  --------- 
 
 
 Special resolutions                         For   Against   Total votes   Withheld 
 8. Disapplication of pre-emption 
  rights                             441,691,580   144,618   441,836,126      5,108 
                                    ------------  --------  ------------  --------- 
 9. Authority to purchase 
  own shares                         441,829,408     9,926   441,839,334      1,900 
                                    ------------  --------  ------------  --------- 
 

Notes:

1. Any proxy votes which are at the discretion of the Chairman have been included in the 'For' total.

2. A vote 'Withheld' is not a vote in law and is not counted in the calculation of the proportion of the votes for and against a resolution.

3. In accordance with the UK Listing Rules only the votes of the holders of Common Shares were actually counted in the voting on resolution number 5. A majority of the votes of the holders of Common Shares were received in favour of this resolution which was duly passed. Out of a total of 372,289,238 votes of holders of Common Shares, 276,529,104 votes were received in favour of this resolution, 34,263 votes were at the discretion of the Chairman, 132,059 votes were against and 3,088 votes were withheld.

The proxy figures for the resolutions will also be displayed on the Company website at www.cathay-intl.com.hk

- ENDS -

For further enquiries, please contact:

 
 Cathay International Holdings Limited 
  Eric Siu (Finance Director)                Tel: [phone] 
  Patrick Sung (Director and Controller) 
 Consilium Strategic Communications 
  Mary-Jane Elliott / Matthew Neal /         Tel: [phone] 
  Lindsey Neville 
 

About Cathay

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on investment opportunities in the growing domestic demand for high quality healthcare products in the PRC and build portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a track record of identifying investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, dicalcium phosphate; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

The Group employs approximately 1,500 people across the PRC, including over 20 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RAGFMMATMBMBBAL

(END) Dow Jones Newswires

June 10, 2019 11:08 ET (15:08 GMT)